Beigene Inks $233M Deal with Merck for Cancer Drug
By Larry Schuster
Wednesday, June 12, 2013
SHANGHAI Beigene Co. Ltd. has licensed a second-generation BRAF inhibitor as a promising preclinical oncology drug to Merck KGaA, of Darmstadt, Germany, for the treatment of melanoma, colorectal cancer and other cancers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.